Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Retained Earnings (2023 - 2025)

Mangoceuticals' Retained Earnings history spans 3 years, with the latest figure at -$37.9 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 2277585.69% year-over-year to -$37.9 million; the TTM value through Sep 2025 reached -$37.9 million, down 2277585.69%, while the annual FY2024 figure was -$9845.0, 99.91% up from the prior year.
  • Retained Earnings for Q3 2025 was -$37.9 million at Mangoceuticals, down from -$31.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$70.0 in Q1 2024 and bottomed at -$37.9 million in Q3 2025.
  • The 3-year median for Retained Earnings is -$6.9 million (2023), against an average of -$10.6 million.
  • The largest annual shift saw Retained Earnings skyrocketed 100.0% in 2024 before it tumbled 2277585.69% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$11.2 million in 2023, then soared by 99.91% to -$9845.0 in 2024, then plummeted by 384642.64% to -$37.9 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Retained Earnings are -$37.9 million (Q3 2025), -$31.6 million (Q2 2025), and -$2221.0 (Q1 2025).